Accelrys releases Pipeline Pilot NGS Collection at Molecular Medicine Tri-Conference

NewsGuard 100/100 Score

Accelrys, Inc. (NASDAQ:ACCL), the leading scientific informatics software and services company, today announced at the Molecular Medicine Tri-Conference its entrance in the rapidly growing next generation sequencing (NGS) market with the release of the NGS Collection for Pipeline Pilot. The NGS Collection, together with Accelrys' industry-leading Pipeline Pilot data pipelining software, provide genomics researchers, bioinformaticians, and information technologists with the tools required to simplify NGS application development, to integrate and automate NGS data processing, and to accelerate the analysis and interpretation of the huge volumes of data generated by current DNA sequencing instruments.

“The NGS Collection represents Accelrys' commitment to a new generation of omics solutions”

"The NGS Collection represents Accelrys' commitment to a new generation of omics solutions," said Dr. Frank Brown, chief science officer at Accelrys. "The NGS Collection for Pipeline Pilot brings an unmatched combination of data processing flexibility, power, and ease-of-use to scientists studying the genetic bases of diseases, responses to drugs, traits of crops, or bio-production of potentially valuable products. With its pioneering graphical development environment and simplified integration framework, Pipeline Pilot helps organizations in industry, academia, and government stay abreast of the NGS innovation curve across a broad range of scientific disciplines. We believe the industry, and high-throughput technologies specifically, are on an important cusp of change that will enable this technology to be leveraged well beyond research."

The Pipeline Pilot NGS Collection enables genomics research groups to better comprehend and assess the massive, complex datasets encountered in today's dynamic NGS research landscape. As with all Pipeline Pilot Collections, the NGS Collection couples a simple drag-and-drop, visual programming environment with powerful algorithmic, data management, and visualization components. This combination empowers a broader range of users, from computational experts to bench scientists, to leverage NGS data in their research — simplifying, standardizing, and accelerating comprehensive NGS analyses. A wide selection of popular algorithms is available, including methods for de novo assembly, mapping reads to reference sequences, identifying polymorphisms and structural variants, measuring RNA expression levels, and identifying transcription factor binding sites. The capabilities found in the NGS Collection are critical to supporting large-scale, enterprise deployments and enabling organizations to derive full value from the vast amounts of data generated by NGS instruments.

The Pipeline Pilot NGS Collection accommodates the high performance computing required by NGS analysis. This includes support for Pipeline Pilot's own distributed processing system as well as third-party systems such as Platform LSF, Altair PBS, and Oracle Grid Engine. The system supports native data formats from all major sequencing platforms including those from Illumina, Life Technologies SOLiD, Roche/454, and others.

Source:

Accelrys, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine